RxDoctor Payments Data

Colleen Brown, PA

Medical · Westlake, OHNPI 1154656890

Payments from drug & device makers

$3,933in general payments, 2019–2025

Across 227 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821
  • Novo Nordisk$386
  • AstraZeneca$327
  • Galderma Laboratories, L.p.$194
  • Amgen$169
  • GSK$158
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$3,933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,933 in reported general payments places this provider in the 85th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$67,393
Medicare patients
128
Services billed
2,466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$50,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$36,365
UbrelvyUbrogepant11$23,451
TrulicityDulaglutide12$12,842
EliquisApixaban17$9,424
SynthroidLevothyroxine Sodium36$2,709
Advair DiskusFluticasone Propion/Salmeterol13$2,624
Duloxetine Hcl53$1,216
Celecoxib24$1,027
Levothyroxine Sodium88$858
Metoprolol Succinate45$817
Atorvastatin Calcium109$799
ValacyclovirValacyclovir Hcl16$617
Esomeprazole Magnesium18$564
Albuterol Sulfate HfaAlbuterol Sulfate26$512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$386$50,94128 claims
GSKTrelegy Ellipta$158$36,36544 claims
AbbVieUbrelvy, Synthroid$821$26,16147 claims
Lilly USA, LLCTrulicity$91$12,84212 claims
PfizerEliquis$98$9,42417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 547 medical providers in Ohio.

Other medical in Westlake

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →